Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement News, In Brief

Executive Summary

Only 11% of physicians plan to apply for EHR federal incentives and appeared about to meet about two-thirds of “meaningful use” requirements, Health Affairs analysis finds; Part D expenditures are increasing by almost 9% annually and rebates are about 11%.

You may also be interested in...



Once Burned, Twice Shy? Pharma Urged To Engage On Entitlement Reform

Despite the current challenges to the ACA, the biopharmaceutical industry should engage proactively with lawmakers as Medicare and Medicaid face major reforms in the coming years, health policy experts urge at PhRMA’s annual meeting.

CMS Reduces Criteria To Qualify For Electronic Health Record Financial Incentives In Final Rule

The final rule on the Medicare and Medicaid electronic health record incentive program addresses concerns that the proposed rule took a one-size-fits-all approach to defining "meaningful use."

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS054412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel